1. Now that griseofulvin is not available, what to do with tinea capitis treatments?
- Author
-
Bonifaz A, Lumbán-Ramírez P, García-Sotelo RS, Vidaurri de la Cruz H, Toledo-Bahena M, and Valencia-Herrera A
- Subjects
- Humans, Administration, Oral, Naphthalenes administration & dosage, Itraconazole administration & dosage, Administration, Topical, Tinea Capitis drug therapy, Tinea Capitis microbiology, Antifungal Agents administration & dosage, Griseofulvin administration & dosage, Terbinafine administration & dosage, Microsporum drug effects, Microsporum isolation & purification, Fluconazole administration & dosage
- Abstract
Introduction: Griseofulvin, discovered in 1939 and commercially available since 1959, was the first oral antifungal agent effective against dermatophytosis, particularly tinea capitis. Although it was eventually superseded by azole antifungals due to its long treatment duration and reliance on keratopoiesis, griseofulvin remains notable for its effectiveness and safety in treating tinea capitis, especially when caused by Microsporum canis . However, due to a decline in cases and commercial unavailability, alternative treatments are now required., Areas Covered: The following topics regarding to other treatments were discussed: (I) The efficacy of alternative antifungal agents such as terbinafine, itraconazole, and fluconazole, in the treatment of tinea capitis. (II) The use and role of topical therapies. (III) Experience in the management of tinea capitis., Expert Opinion: The usefulness of oral terbinafine as a replacement for griseofulvin in the treatment of tinea capitis and why it is the preferred drug in elderly patients was discussed. Challenges with Microsporum spp. and the use of fluconazole in pediatric patients were also analyzed. Support for the use of topical treatment as an adjunctive treatment for tinea capitis was highlighted.
- Published
- 2024
- Full Text
- View/download PDF